OncLive.com ✓

@OncLive · New Jersey, USA · joined 28 May 2009

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

50 274Followers

2 005Following

120 045Posts total

3.4KViews on collected posts

Against accounts of the same size

5 posts from the last 90 days, next to the 10K–100K follower range. below its peers on both reach and engagement.

Median views120this account2 896median for 10K–100K

Reach, %0.24%this account9.51%median for 10K–100K

Engagement, %0.83%this account1.56%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	120	2 896	0.04×
Reach (views ÷ followers)	0.24%	9.51%	0.03×
Engagement rate	0.83%	1.56%	0.54×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.9K26 Aug

1773 Sep

120

117

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.96%26 Aug

2.82%3 Sep

0.83%

0.00%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.56%.

What the audience does

Likes70.6%24 in total

Reposts20.6%7 in total

Replies2.9%1 in total

Quotes5.9%2 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology Dive into the efficacy and safety highlights: https://t 66 views · 0 likes · 0 reposts · 0 replies 03 Sep 2026 🩸Excited for @SocietyofHemOnc 2026? We've got you covered with expert insights on all the most important things to watch for going into the meeting. Full details 📈: https://t.co/UjtkEpaSWM #leusm #lymsm #mmsm #mpnsm #oncology @AaronGerds @LymphClinician @RaajitRampal https://t 117 views · 0 likes · 0 reposts · 0 replies 03 Sep 2026 Register now to attend the launch broadcast for JIDEYTRO™ (zidesamtinib), hosted by Dr. Mark Socinski, MD. Learn about trial data, efficacy outcomes, and safety profile of JIDEYTRO (zidesamtinib). Click here to sign-up: https://t.co/HDV2XI8Qku https://t.co/s4f8wWaORy 120 views · 1 likes · 0 reposts · 0 replies 03 Sep 2026 📰 GLP-1s are generating significant buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression. #bcsm #oncology Read insights from Deena Graham, MD, of @JTCancerCenter and @HMHNewJersey here: https://t.co/a2g84CZeJ0 177 views · 4 likes · 1 reposts · 0 replies 03 Sep 2026 🚨BREAKING: The news the pancreatic cancer field has been awaiting is here. The @FDA has approved daraxonrasib for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent h 2.9K views · 19 likes · 6 reposts · 1 replies 26 Aug 2026